Patients at risk of blindness from wet age-related macular degeneration (AMD) can now receive previo...
Patients at risk of blindness from wet age-related macular degeneration (AMD) can now receive previously disallowed treatment for the condition following final guidance from the National Institute of Clinical Excellence (NICE).
The body ruled that two drugs with the trade name of Lucentis and Macugen will now be supplied on the NHS to affected patients if certain criteria are met.
The criteria include: indications that the condition is worsening, no permanent structural damage to the central fovea of the eye and that any treatment is having a positive effect on the condition.
Steve Winyard, head of campaigns at The Royal National Institute for the Blind said the ruling was a "victory for thousands" and would bring "overwhelming relief to desperate people across the country".
